Prognostic Value of Albumin-to-Fibrinogen Ratio for 28-Day Mortality among Patients with Sepsis from Various Infection Sites

Shuai Li,1,2 Yawei Shen,1,2 Bowen Chang,3 and Nan Wang1,2

1Department of Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
2Anhui Public Health Clinical Center, Hefei, Anhui, China
3The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China

Correspondence should be addressed to Nan Wang; 523601821@qq.com

Received 13 January 2022; Revised 25 June 2022; Accepted 5 July 2022; Published 10 August 2022

Academic Editor: Markus H. Gräler

Copyright © 2022 Shuai Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. This study investigated the prognostic value of the albumin-to-fibrinogen ratio (AFR) in patients with sepsis as a consequence of infection at various sites. Methods. A total of 300 patients with sepsis caused by various infection sites, who met the diagnostic criteria for sepsis hospitalized in the intensive care unit, were enrolled in this study. The observational endpoint was 28-day mortality. Cox proportional hazard regression analysis was performed to determine the potential prognostic factors for 28-day mortality in these septic patients. Receiver operating characteristic (ROC) curve analysis was used to evaluate and compare the prognostic factors for 28-day mortality. Results. Of 300 participants, 147 died, corresponding to a 28-day mortality of 49% (147/300). Baseline Acute Physiology and Chronic Health Evaluation (APACHE II) score (hazard ratio (HR) 1.18 (95% confidence interval (CI) 1.07–1.30); P < 0.001), baseline lactic acid level (HR 1.27 (95% CI 1.08–1.50); P = 0.005), the presence of septic shock (HR 21.44 (95% CI 2.51–182.76); P = 0.005), and baseline AFR (HR 0.70 (95% CI 0.62–0.80); P < 0.001) were independent prognostic factors for 28-day mortality in patients with sepsis according to multivariate Cox analysis. Baseline AFR was an effective predictor of 28-day mortality, with an area under the ROC curve (AUC) of 0.700, and a specificity and sensitivity of 90.8% and 42.1%, respectively. A low baseline AFR level was associated with increased 28-day sepsis-related mortality. The quadruple index, which included the APACHE II score, lactic acid, septic shock, and AFR, showed a more accurate predictive value for septic patients than the APACHE II score, lactic acid, septic shock, and AFR alone, with an AUC of 0.922, and specificity and sensitivity of 86.9% and 83.6%, respectively. Moreover, the triple index, which included the APACHE II score, lactic acid, and septic shock, showed a significantly lower prognostic value for 28-day mortality compared with the ROC curve of the quadruple index and triple index, with an AUC of 0.877 and specificity and sensitivity of 77.8% and 82.3%, respectively. Conclusions. The results of this study demonstrate that AFR is an independent protective factor for predicting 28-day mortality in patients with sepsis due to various infection sites. AFR combined with the APACHE II score, lactic acid, and septic shock showed a higher prognostic value for sepsis prognosis.

1. Introduction

Sepsis is a syndrome involving systemic multiple organ dysfunction due to infection. It is the most common cause of death and accounts for substantial economic burden to adults hospitalized in intensive care units (ICUs) [1, 2]. Despite advances in medical and scientific research, however, millions of individuals worldwide continue to be affected by sepsis each year, with a mortality rate of ≥25% [3]. Clinical studies have shown that early detection of sepsis and timely targeted treatment of prognostic risk factors can significantly reduce its mortality rate [4, 5]. This emphasizes the need to identify reliable prognostic factors to accurately predict sepsis outcomes and to accelerate the design of individualized treatment strategies. Sepsis involves complex systemic inflammatory network effects, immune dysfunction, and impaired coagulation function and so on [6]. Accurate and effective biomarkers are important for the diagnosis
and prognosis of sepsis. Previous studies have reported that C-reactive protein (CRP) and procalcitonin (PCT) are valuable prognostic factors, which are not satisfactory for predicting sepsis-related mortality [7]. Recently, there have been many studies on the relationship between albumin and fibrinogen levels and sepsis prognosis [5, 8].

Accumulating evidence has shown that serum albumin level is closely associated with inflammation and nutrition and is significantly associated with prognosis in patients with sepsis [9–11]. Fibrinogen, another essential inflammatory biomarker of acute-phase inflammation, is a key protein in the coagulation cascade and plays an important role in the prognosis of sepsis, similar to CRP [12, 13]. Studies have shown that the index integrating albumin and fibrinogen, e.g., albumin-to-fibrinogen ratio (AFR), presents not only the status of inflammation and nutrition but also the coagulation function. With improved consistency compared to albumin or fibrinogen alone, AFR could amplify the sensitivity of inflammatory status and is superior in assessing the prognostic value of various diseases [14–16].

However, to our knowledge, few studies have evaluated the role of AFR in patients with sepsis. As such, the present investigation aimed to assess the utility of selected prognostic factors, including AFR, in patients with sepsis from various infection sites.

2. Material and Methods

2.1. Study Design. This retrospective study was approved by the Ethics Committee of the Affiliated Hospital of Anhui Medical University (Hefei, Anhui province, China). This study initially enrolled eligible patients who were admitted to the ICU of Affiliated Hospital of Anhui Medical University between August 2018 and August 2021. The inclusion criteria were as follows: (1) adults (male and female) > 18 years of old; (2) presence of sepsis according to the definition criteria (Sepsis-3) [1, 17] caused by various foci of infection; and (3) diagnosis of sepsis within 24h after admission to the ICU. Patients < 18 years of age, who did not complete the 28-day follow-up data, who were pregnant, patients with advanced cancer (patients with solid tumors or hematologic malignancies who failed standard therapy or relapsed, and the presence of radiographic evidence of metastatic disease in solid tumors was required) [18], severe malnutrition (weight loss > 10% within the last 6 months, or >20% after 6 months) [19], coagulopathy (e.g., hemophilia), hepatic dysfunction (e.g., decompensated cirrhosis), and immunodeficiency diseases (e.g., systemic lupus erythematosus), and those receiving glucocorticoid, radiotherapy, chemotherapy, or immunotherapy were excluded. All participants were treated and managed in the ICU according to international guidelines for sepsis and septic shock [4]. The observational endpoint was 28-day mortality. Telephone follow-up was used to assess patients who were discharged from hospital before 28 days.

2.2. Definition of Sepsis. Sepsis was diagnosed according to the Third International Consensus Definitions as an acute change in total sequential organ failure assessment (SOFA) score ≥ 2 points consequent to the infection.

2.3. Data Collection. Clinical data were collected from the medical records of each enrolled patient. Demographic information included age and gender, baseline vital signs, including body temperature, heart rate, respiratory rate, and mean arterial pressure, and the intervention strategies including mechanical ventilation and continuous renal replacement therapy. Detailed data regarding common comorbidities, including hypertension, diabetes mellitus, chronic lung disease, cardiac disease, and chronic renal disease, were extracted from the database. Sites of infection included the bloodstream and the respiratory, genitourinary, gastrointestinal, hepatobiliary, and central nervous systems, according to the results of microbial culture. Patient with suspected site of infection without clear pathogen was considered an unknown site of infection. In addition, the Acute Physiology and Chronic Health Evaluation (APACHE) II score [20], SOFA score [21], and Glasgow Coma Scale (GCS) [22] score were calculated based on methods reported in the literature. Laboratory investigations included white blood cell (WBC) counts, neutrophils (NEU), lymphocytes (LYM), hemoglobin (Hb), platelets (PLTs), pH, lactic acid, CRP, PCT, creatinine, blood urea nitrogen (BUN), albumin, fibrinogen, and AFR. Baseline vital signs were obtained on the day of sepsis diagnosis. Intervention strategies were administered after sepsis diagnosis. The severity of the sepsis was assessed within 24h of sepsis diagnosis. Peripheral venous and arterial blood samples and samples from infection sources were collected on the day of sepsis diagnosis and measured by our institution laboratory to obtain laboratory data.

2.4. Statistical Analysis. Empower (R) (http://www .empowerstats.com, X&Y Solutions, Inc., Boston, MA, USA) and R (http://www.R-project.org) were used for all statistical analyses. Continuous variables are presented as the mean ± standard error (SE) or the median, and categorical variables are presented as number with percentages. Initially, the Kolmogorov–Smirnov test was used to examine whether the
3. Results

3.1. Baseline Characteristics and Clinical Outcomes. As demonstrated by the flow chart diagram seen in Figure 1. A total of 329 potentially eligible patients with sepsis were initially enrolled in the present study; however, 29 were excluded in accordance with the exclusion criteria. Ultimately, therefore, 300 patients were included in the data analysis. The mean age of the subjects was 62.9 years, and the majority were male (198/300 (66%)). The 28-day mortality of all study participants was 49% (147/300). The most frequent infection sites were the respiratory and genitourinary systems and the bloodstream. Moreover, 87 sepsis patients failed to identify the site of infection. The baseline characteristics of survivors versus non-survivors are summarized in Table 1. No significant differences were noted between the two groups (i.e., survivors versus non-survivors) with regard to age and gender distribution. Common comorbidities, including hypertension, diabetes mellitus, cardiac disease, and chronic renal disease, were not remarkably different, except for chronic lung disease between the survivor and nonsurvivor groups. Additionally, baseline vital signs were statistically different in addition to body temperature between the two groups. Moreover, patients with septic shock and those who received mechanical ventilation and continuous renal replacement therapy exhibited higher 28-day mortality rates. Compared with the survivor group, the nonsurvivor group had significantly higher APACHE II and SOFA scores and

| Parameters                              | Survivors (n = 153) | Nonsurvivors (n = 147) | P value  |
|----------------------------------------|--------------------|------------------------|---------|
| Age (years)                            | 61.8 ± 15.6        | 64.1 ± 15.2            | 0.200   |
| Gender, n (%)                          | —                  | —                      | 0.089   |
| Male                                   | 94 (61.4%)         | 104 (70.7%)            | —       |
| Female                                 | 59 (38.6%)         | 43 (29.3%)             | —       |
| Comorbidities                          | —                  | —                      | —       |
| Hypertension, n (%)                    | 28 (18.3%)         | 38 (25.9%)             | 0.115   |
| Diabetes mellitus, n (%)               | 22 (14.4%)         | 30 (20.4%)             | 0.168   |
| Chronic lung disease, n (%)            | 3 (2.0%)           | 10 (6.8%)              | 0.038*  |
| Cardiac disease, n (%)                 | 12 (7.8%)          | 16 (10.9%)             | 0.365   |
| Chronic renal disease, n (%)           | 9 (5.9%)           | 17 (11.6%)             | 0.080   |
| Body temperature (°C)                  | 37.1 ± 1.0         | 37.3 ± 1.2             | 0.124   |
| Heart rate (per minute)                | 105.8 ± 24.5       | 116.0 ± 26.6           | <0.001* |
| Respiratory rate (per minute)          | 21.2 ± 6.0         | 24.7 ± 7.3             | <0.001* |
| Mean atrial pressure (mmHg)            | 79.4 ± 18.1        | 75.4 ± 20.9            | 0.007*  |
| Mechanical ventilation, n (%)          | 82 (53.6%)         | 105 (71.4%)            | 0.001*  |
| Continuous renal replacement therapy, n (%) | 29 (19.0%) | 41 (27.9%) | 0.067 |
| Septic shock, n (%)                    | 111 (72.5%)        | 145 (98.6%)            | <0.001* |
| APACHE II score                        | 15.9 ± 5.1         | 25.5 ± 7.7             | <0.001* |
| SOFA score                             | 8.2 ± 4.0          | 12.3 ± 4.0             | <0.001* |
| GCS score                              | 15.0 (P25 12.0–P75 15.0) | 7.0 (P25 3.0–P75 14.0) | <0.001* |
| Site of infection                      | —                  | —                      | 0.004*  |
| Respiratory system, n (%)              | 32 (20.9%)         | 42 (28.6%)             | —       |
| Genitourinary system, n (%)            | 10 (6.5%)          | 12 (8.2%)              | —       |
| Gastrointestinal system, n (%)         | 30 (19.6%)         | 27 (18.3%)             | —       |
| Bloodstream, n (%)                     | 22 (14.5%)         | 34 (23.1%)             | —       |
| Hepatobiliary system, n (%)            | 0 (0.0%)           | 2 (1.4%)               | —       |
| Central nervous system, n (%)          | 0 (0.0%)           | 2 (1.4%)               | —       |
| Unknown, n (%)                         | 59 (38.5%)         | 28 (19%)               | —       |

APACHE II: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; GCS: Glasgow Coma Scale; P values were calculated by chi-square test, Fisher’s exact test, Student’s t-test, or Mann–Whitney U test; *P < 0.05 indicates statistical significance.
Table 2: Laboratory variables of patients with sepsis between the survivor and nonsurvivor groups.

| Parameters   | Survivors (n = 153) | Nonsurvivors (n = 147) | P value |
|-------------|---------------------|------------------------|---------|
| WBC (10^9/L) | 14.9 ± 9.0          | 14.6 ± 14.9            | 0.850   |
| NEU (10^9/L) | 13.3 ± 8.4          | 12.9 ± 12.8            | 0.743   |
| LYM (10^9/L) | 0.9 ± 1.8           | 0.9 ± 1.1              | 0.988   |
| Hb (g/L)     | 105.0 ± 22.3        | 102.4 ± 30.1           | 0.400   |
| PLTs (10^9/L)| 115.2 ± 85.3        | 101.6 ± 85.3           | 0.169   |
| pH           | 7.5 ± 1.3           | 7.3 ± 0.1              | <0.001* |
| Lactic acid (mmol/L) | 3.5 ± 2.2           | 6.0 ± 3.5              | <0.001* |
| CRP (mg/L)   | 151.4 ± 98.3        | 163.7 ± 97.7           | 0.280   |
| PCT (ng/mL)  | 66.3 ± 41.8         | 60.9 ± 39.7            | 0.254   |
| BUN (mmol/L) | 13.3 ± 8.4          | 19.2 ± 13.9            | <0.001* |
| Creatinine (μmol/L) | 215.7 ± 183.7      | 278.1 ± 6.07           | 0.005*  |
| Albumin (g/L) | 27.7 ± 5.6          | 25.0 ± 6.1             | <0.001* |
| Fibrinogen (g/L) | 3.0 ± 1.2           | 4.0 ± 1.8              | <0.001* |
| AFR          | 11.0 ± 7.0          | 7.5 ± 3.6              | <0.001* |

WBC: white blood cell; NEU: neutrophil; LYM: lymphocyte; Hb: hemoglobin; PLTs: platelets; CRP: C-reactive protein; PCT: procalcitonin; BUN: blood urea nitrogen; AFR: albumin-to-fibrinogen ratio; P values were calculated by Student’s t-test or Mann–Whitney U test; *P < 0.05 indicates statistical significance.

lower baseline GCS scores. Finally, the site of infection was significantly associated with prognosis among patients with sepsis.

3.2. Laboratory Variables. A detailed comparison of laboratory variables between the survivor and nonsurvivor groups is presented in Table 2. In terms of WBC, NEU, LYM, Hb, PLT, CRP, and PCT, there was no obvious correlation with prognosis in either of the two patient groups. The nonsurvivor group was significantly associated with higher levels of lactic acid, BUN, creatinine, and fibrinogen compared with the survivor group. In contrast, patients with sepsis who experienced 28-day mortality exhibited significantly lower levels of albumin, AFR, and pH than those who survived beyond 28 days.

3.3. Risk Factors for 28-Day Mortality. As shown in Tables 3, 17 potential risk factors (P < 0.05) (Tables 1 and 2), age and gender for possible prognostic values for 28-day mortality in the two groups were evaluated using univariate and multivariate Cox proportional hazards regression analyses. Univariate Cox analysis revealed that history of chronic lung disease, the presence of septic shock, use of mechanical ventilation, baseline heart rate, respiratory rate, mean atrial pressure, GCS, APACHE II score, SOFA score, site of infection, pH, lactic acid, BUN, creatinine, albumin, fibrinogen, and AFR were probable valuable prognostic factors in septic patients. More specifically, age, gender and all potential risk factors with a P value < 0.1 in the univariate Cox analysis were entered into multivariate Cox regression analysis. However, AFR consists of albumin and fibrinogen. As indicated in Figure 2, the ROC curve analysis was used to investigate which of the two independent components and AFR were more suitable for inclusion in the multivariate Cox regression analysis. AFR revealed higher area under the ROC curve (AUC) value in comparison to fibrinogen (P = 0.001), as a probable predictor of 28-day mortality in patients with sepsis. There was a trend toward higher AUC value than albumin, although the difference was not statistically significant (P = 0.095). Therefore, AFR was selected for multivariate Cox regression analysis. As shown in Table 3, the results revealed that baseline APACHE II score, baseline lactic acid level, the presence of septic shock, and baseline AFR were independently associated with 28-day mortality in patients with sepsis from various infection sites.

3.4. Prognostic Value of Risk Factors, including AFR, for 28-Day Mortality. As shown in Figure 3 and Table 4, the results further demonstrated that baseline AFR was strongly associated with 28-day mortality in patients with sepsis, with an AUC of 0.700 and specificity and sensitivity of 90.8% and 42.1%, respectively. ROC curve analysis revealed that the optimal cut-off value for AFR was 5.86. Moreover, compared with APACHE II score and lactic acid level, ROC curve analysis revealed that AFR had a weak prognostic value for 28-day mortality in patients with sepsis. However, the combined quadruple index, which included the APACHE II score, lactic acid, septic shock, and AFR alone, was a better predictor of 28-day mortality in patients with sepsis than the APACHE II score, lactic acid, septic shock, and AFR alone, with an AUC of 0.922, and specificity and sensitivity of 86.9% and 83.6%, respectively.

3.5. Comparison of Quadruple Index and Triple Index for Predicting 28-Day Mortality. As shown in Figure 4 and Table 4, to further validate the prognostic value of baseline AFR for 28-day mortality in patients with sepsis, we analyzed the triple index comprising the APACHE II score, lactic acid, septic shock, and AFR alone, with an AUC of 0.877 and specificity and sensitivity of 77.8% and 82.3%, respectively. Compared with the ROC curve of the quadruple index, the addition of AFR significantly increased the prognostic value of 28-day mortality in patients with sepsis.

4. Discussion

The results of this retrospective observational study revealed that a high baseline APACHE II score, a high baseline lactic acid level, the presence of septic shock, and a low baseline AFR were independently associated with a greater risk of 28-day mortality in patients with sepsis caused by various foci of infection. To our knowledge, few studies have examined AFR as an independent prognostic biomarker in patients with sepsis. Moreover, AFR along with the APACHE II score, lactic acid, and septic shock showed a higher prognostic value of 28-day mortality than the APACHE II score, lactic acid, septic shock, and AFR alone in patients with sepsis.
Sepsis is defined as a life-threatening, infection-induced, decompensated host response leading to multiple organ dysfunction [1]. Early recognition of and timely intervention for sepsis are indispensable for improving the survival rate and preventing the transition to septic shock, which has a mortality rate ≥ 40% [3, 23]. Moreover, an increasing number of studies have attempted to explore effective prognostic factors in attempts to reduce sepsis-related mortality [10, 24, 25]. However, prognostic factors have not been completely identified in patients with sepsis.

Our results from multivariate Cox regression analysis demonstrated that baseline APACHE II score, baseline lactic acid level, septic shock, and baseline AFR were independent prognostic factors in septic patients caused by various infection sites. The APACHE II score is extensively used among critically ill patients with sepsis in the ICU, and it is accurate for the prognosis, comparable the SOFA score [1, 26]. Our results are also consistent with the apparent correlation between the APACHE II score and prognosis of sepsis. Evidence-based recommenda-

| Variables                        | Univariable          | Multivariable         |
|----------------------------------|----------------------|-----------------------|
|                                  | HR (95% CI)          | P value               | HR (95% CI)          | P value               |
| Age                              | 1.01 (0.99, 1.02)    | 0.200                 | 1.01 (0.98, 1.03)    | 0.645                 |
| Gender (female)                  | 0.66 (0.41, 1.07)    | 0.090                 | 0.80 (0.35, 1.80)    | 0.588                 |
| Chronic lung disease (yes vs. no)| 3.68 (0.99, 13.64)   | 0.052                 | 5.55 (0.66, 46.59)   | 0.114                 |
| Heart rate (per minute)          | 1.02 (1.01, 1.03)    | <0.001*               | 0.99 (0.98, 1.01)    | 0.512                 |
| Respiratory rate (per minute)    | 1.08 (1.05, 1.13)    | <0.001*               | 1.01 (0.95, 1.08)    | 0.768                 |
| Mean arterial pressure (mmHg)    | 0.99 (0.98, 1.00)    | 0.082                 | 1.00 (0.98, 1.02)    | 0.732                 |
| Mechanical ventilation (yes vs. no)| 2.16 (1.34, 3.49)    | 0.002*               | 1.75 (0.80, 3.82)    | 0.162                 |
| Septic shock (yes vs. no)        | 27.43 (6.50, 115.76) | <0.001*               | 21.44 (2.51, 182.76) | 0.005*                |
| APACHE II score                  | 1.25 (1.19, 1.32)    | <0.001*               | 1.18 (1.07, 1.30)    | <0.001*               |
| SOFA score                       | 1.28 (1.19, 1.36)    | <0.001*               | 1.03 (0.91, 1.16)    | 0.616                 |
| GCS score                        | 0.75 (0.70, 0.81)    | <0.001*               | 0.92 (0.81, 1.05)    | 0.197                 |
| Site of infection                |                      |                       |                      |                       |
| Respiratory infection (yes vs. no)| 1.0 (reference)      | —                     | 1.0 (reference)      | —                     |
| Genitourinary infection (yes vs. no)| 0.91 (0.35, 2.38)  | 0.854                 | —                     | —                     |
| Gastrointestine infection (yes vs. no)| 0.69 (0.34, 1.37)  | 0.287                 | —                     | —                     |
| Bloodstream infection (yes vs. no)    | 1.18 (0.58, 2.39)   | 0.650                 | —                     | —                     |
| Hepatobiliary infection (yes vs. no)    | 4386905 (0, co)     | 0.988                 | —                     | —                     |
| Central nervous infection (yes vs. no)    | 4386905 (0, co)     | 0.988                 | —                     | —                     |
| Unknown (yes vs. no)             | 0.36 (0.19,0.69)    | <0.001*               | 0.81 (0.26, 2.51)    | 0.708                 |
| pH                               | 0.004 (0.001, 0.029) | <0.001*               | 0.35 (0.01, 11.65)   | 0.556                 |
| Lactic acid (mmol/L)             | 1.42 (1.28, 1.58)    | <0.001*               | 1.27 (1.08, 1.50)    | 0.005*                |
| BUN (mmol/L)                     | 1.06 (1.03, 1.09)    | <0.001*               | 1.04 (0.98, 1.09)    | 0.163                 |
| Creatinine (μmol/L)              | 1.002 (1.000, 1.003) | 0.007*               | 1.00 (0.99, 1.0)     | 0.068                 |
| Albumin (g/L)                    | 0.92 (0.88, 0.96)    | <0.001*               | —                     | —                     |
| Fibrinogen (g/L)                 | 1.52 (1.29, 1.80)    | <0.001*               | —                     | —                     |
| AFR                             | 0.84 (0.79, 0.90)    | <0.001*               | 0.70 (0.62, 0.80)    | <0.001*               |

APACHE II: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; GCS: Glasgow Coma Scale; BUN: blood urea nitrogen; AFR: albumin-to-fibrinogen ratio; HR: hazard ratio; CI: confidence interval; *P < 0.05 indicates statistical significance.
High blood lactate level is a well-known biomarker associated with poor prognosis among patients with sepsis, which is significantly increased by tissue hypoxia [30]. Our findings provide evidence supporting that a high baseline level of lactic acid is associated with increased mortality in patients with sepsis. An increasing number of studies and sepsis guidelines suggest that lactate levels > 2 mmol/L are more sensitive in predicting prognosis in patients who experience septic shock [4, 31]. A previous study by Casserly et al. concluded that lactate levels > 4 mmol/L were associated with higher 28-day mortality rates [32]. This study is consistent with our best threshold of blood lactate levels from the ROC curve analysis, which may provide a more accurate prognostic value for 28-day mortality.

Our study also found that AFR, a new biomarker, was strongly associated with 28-day mortality in patients with sepsis caused by various infection sites. AFR consists of albumin and fibrinogen, which are widely used as prognostic factors in patients with sepsis [5, 8]. A previous report by Don et al. indicated that inflammation leads to low serum levels of albumin due to decreased synthesis and increased catabolism. Low albumin levels significantly influence the pharmacokinetics of antimicrobials, resulting in decreased antibacterial effects, except for poor nutritional status and organic function [33]. This may explain why albumin is closely associated with sepsis prognosis. However, study by Godinez-Vidal et al. reported that albumin can be considered a predictor of severity, although not a predictor of mortality [34]. Serum fibrinogen expression is notably increased in patients with a high inflammatory status and can promote the activation of coagulation and aggregation of PLT [16, 35]. Previous studies have shown that dysregulation of fibrinogen expression leads to a poor prognosis of disseminated intravascular coagulation in patients with sepsis [13].

In summary, the levels of albumin or fibrinogen may be not effective prognosis factor in predicting sepsis-related mortality.

AFR, the ratio of albumin to fibrinogen, can be used as a timely indicator of the nutritional status, inflammatory status, and coagulation function of patients [36–38] and is also an effective marker to predict the prognosis of various diseases, including lung cancer, rheumatoid arthritis, and acute kidney injury [16, 36, 39]. The prognosis of sepsis is closely associated with nutritional status, inflammatory status, and coagulation function of patients [4]. These associations may explain the potential relationship between AFR and sepsis prognosis. Tai et al. first reported AFR as an independent prognostic factor in patients with sepsis, in whom sepsis was caused by abdominal infection after surgical treatment [14]. Our study initially evaluated the role of AFR in patients with sepsis caused by various infection sites. Multivariate Cox regression and ROC curve analysis revealed that a low baseline AFR was significantly associated with increased 28-day mortality in patients with sepsis. While, compared with the ROC curve of the combined index of quadruple and triple, the importance of AFR for prognostic value in patients with sepsis was further validated. Consequently, individualized therapies can be designed according to the baseline AFR, to improve the prognosis of sepsis. In this study, many clinical predictors of prognosis of sepsis were identified. However, compared with the APACHE II score and lactic acid level, AFR had a weak predictive value.

Figure 2: The ROC curve analysis of albumin, fibrinogen, and AFR for the prognostic value of 28-day mortality in patients with sepsis. ROC: receiver operating characteristic; AUC: area under the curve; AFR: albumin-to-fibrinogen ratio.

Figure 3: The ROC curve analysis of APACHE II score, lactic acid, septic shock, AFR, and quadruple index for the prognostic value of 28-day mortality in patients with sepsis. ROC: receiver operating characteristic; AUC: area under the curve; APACHE II: Acute Physiology and Chronic Health Evaluation; AFR: albumin-to-fibrinogen ratio; quadruple index includes APACHE II score, lactic acid, septic shock, and AFR;
for the prognosis of sepsis according to the ROC curve analysis. Therefore, we applied multiple factors to evaluate the predictive efficacy of prognosis to ensure reliability and accuracy. According to current data, AFR combined with the APACHE II score, lactic acid, and septic shock could increase the predictive value of prognosis compared with the APACHE II score, lactic acid, septic shock, and AFR alone in patients with sepsis. In other words, the combination of high baseline APACHE II score, high lactic acid level, the presence of septic shock, and low baseline AFR showed a higher risk of predicting 28-day mortality in patients with sepsis. To our knowledge, this is the first study to describe the combination of four predictive factors for the prognosis of sepsis, which may provide a novel direction for management of septic patients.

Several limitations of this study should be considered. First, this is a single-center, retrospective study with a relatively small sample size. Second, the clinical prognostic value of AFR is slight higher than albumin and fibrinogen in our study. More and further studies are needed. Last, it is unclear whether methods to improve the baseline AFR levels can significantly improve clinical prognosis.

5. Conclusion

Our study demonstrated that AFR was an independent predictor of 28-day mortality in patients with sepsis caused by various infection sites. AFR combined with APACHE II score, lactic acid, and septic shock showed a higher prognostic value for sepsis prognosis. However, prospective multicenter studies with larger sample sizes are needed to verify the prognostic value of AFR in patients experiencing sepsis.

Data Availability

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Conflicts of Interest

All authors declare that they have no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Shuai Li and Yawei Shen jointly contributed to the experiment and the writing. Nan Wang and Bowen Chang took overall control of the study. All authors read and approved the manuscript.

Acknowledgments

The authors would like to thank all the individuals who offered help and advice on this study. In addition, we would like to thank Editage (http://www.editage.cn) for English language editing.
References

[1] M. Singer, C. S. Deutschman, C. W. Seymour et al., "The third international consensus definitions for sepsis and septic shock (Sepsis-3)," JAMA, vol. 315, no. 8, pp. 801–810, 2016.

[2] R. Gauer, D. Forbes, and N. Boyer, "Sepsis: diagnosis and management," American Family Physician, vol. 101, no. 7, pp. 409–418, 2020.

[3] M. Cecconi, L. Evans, M. Levy, and A. Rhodes, "Sepsis and septic shock," Lancet, vol. 392, no. 10141, pp. 75–87, 2018.

[4] A. Rhodes, L. E. Evans, W. Alhazzani et al., "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016," Intensive Care Medicine, vol. 43, no. 3, pp. 304–377, 2017.

[5] M. Yin, L. Si, W. Qin et al., "Predictive value of serum albumin level for the prognosis of severe sepsis without exogenous human albumin administration: a prospective cohort study," Journal of Intensive Care Medicine, vol. 33, no. 12, pp. 687–694, 2018.

[6] R. Pool, H. Gomez, and J. A. Kellum, "Mechanisms of organ dysfunction in sepsis," Critical Care Clinics, vol. 34, no. 1, pp. 63–80, 2018.

[7] L. Su, L. Feng, Q. Song et al., "Diagnostic value of dynamics serum sCD163, sTREM-1, PCT, and CRP in differentiating sepsis, severity assessment, and prognostic prediction," Mediators of Inflammation, vol. 2013, Article ID 969875, 9 pages, 2013.

[8] X. Tang, L. Shao, J. Dou et al., "Fibrinogen as a prognostic predictor in pediatric patients with sepsis: a database study," Mediators of Inflammation, vol. 2020, Article ID 9153620, 10 pages, 2020.

[9] A. P. Delaney, A. Dan, J. McCaffrey, and S. Finfer, "The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis," Critical Care Medicine, vol. 39, no. 2, pp. 386–391, 2011.

[10] The SAFE Study Investigators, "Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis," Intensive Care Medicine, vol. 37; no. 1, pp. 86–96, 2011.

[11] O. Fiala, M. Pesek, J. Finek et al., "Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib," Neoplasma, vol. 63, no. 3, pp. 471–476, 2016.

[12] T. Kijima, T. Arigami, Y. Uchikado et al., "Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma," Cancer Science, vol. 108, no. 2, pp. 193–199, 2017.

[13] J. K. Signoff, J. C. Fitzgerald, D. T. Teachey, F. Balamuth, and S. L. Weiss, "Hypofibrinogenemia is associated with poor outcome and secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome in pediatric severe sepsis," Pediatric Critical Care Medicine, vol. 19, no. 5, pp. 397–405, 2018.

[14] H. Tai, Z. Zhu, H. Mei, W. Sun, and W. Zhang, "Albumin-to-fibrinogen ratio independently predicts 28-day mortality in patients with periitonitis-induced sepsis," Mediators of Inflammation, vol. 2020, Article ID 7280708, 7 pages, 2020.

[15] W. Yu, Z. Ye, X. Fang, X. Jiang, and Y. Jiang, "Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer," Journal of Ovarian Research, vol. 12, no. 1, p. 88, 2019.

[16] F. Cao, X. Chen, G. Huang et al., "The albumin-to-fibrinogen ratio independently predicts acute kidney injury in infants with ventricular septal defect undergoing cardiac surgery with cardiopulmonary bypass," Frontiers in Pediatrics, vol. 9, article 682839, 2021.

[17] M. Levy, M. P. Fink, J. C. Marshall et al., "2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference," Intensive Care Medicine, vol. 29, no. 4, pp. 530–538, 2003.

[18] W. K. Kelly, O. A. O’Connor, L. M. Krug et al., "Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer," Journal of Clinical Oncology, vol. 23, no. 17, pp. 3923–3931, 2005.

[19] G. L. Jensen, T. Cederholm, M. Correia et al., "GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community," JPEN Journal of Parenteral and Enteral Nutrition, vol. 43, no. 1, pp. 32–40, 2019.

[20] W. A. Knaus, E. A. Draper, D. P. Wagner, and J. E. Zimmerman, "APACHE II," Critical Care Medicine, vol. 13, no. 10, pp. 818–829, 1985.

[21] J.-L. Vincent, R. Moreno, J. Takala et al., "The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine," Intensive Care Medicine, vol. 22, no. 7, pp. 707–710, 1996.

[22] G. Teasdale and B. Jennett, "Assessment of coma and impaired consciousness: a practical scale," The Lancet, vol. 2, no. 7872, pp. 81–84, 1974.

[23] E. Vail, H. B. Gershengorn, M. Hua, A. J. Walkey, G. Rubenfeld, and H. Wunsch, "Association between US nor-epinephrine shortage and mortality among patients with septic shock," JAMA, vol. 317, no. 14, pp. 1433–1442, 2017.

[24] M. Sandquist and H. R. Wong, "Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment," Expert Review of Clinical Immunology, vol. 10, no. 10, pp. 1349–1356, 2014.

[25] J. L. Vincent, Y. Sakr, C. L. Sprung et al., "Sepsis in European intensive care units: results of the SOAP study," Critical Care Medicine, vol. 34, no. 2, pp. 344–353, 2006.

[26] J. Chen, X. Shi, M. Diao et al., "A retrospective study of sepsis-associated encephalopathy: epidemiology, clinical features and adverse outcomes," BMC Emergency Medicine, vol. 20, no. 1, p. 77, 2020.

[27] W. K. Kuo, C. C. Hua, C. C. Yu, Y. C. Liu, and C. Y. Huang, "The cancer control status and APACHE II score are prognostic factors for critically ill patients with cancer and sepsis," Journal of the Formosan Medical Association, vol. 119, no. 1, pp. 276–281, 2020.

[28] S. Santhakumaran, A. Gordon, A. T. Prevost, C. O’Kane, D. F. McAuley, and M. Shankar-Hari, "Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials," Critical Care, vol. 23, no. 1, p. 156, 2019.

[29] P. Calle, L. Cerro, J. Valencia, and F. Jaimez, "Usefulness of severity scores in patients with suspected infection in the emergency department: a systematic review," The Journal of Emergency Medicine, vol. 42, no. 4, pp. 379–391, 2012.

[30] B. Suetrong and K. R. Walley, "Lactic acidosis in sepsis: it’s not all anaerobic: implications for diagnosis and management," Chest, vol. 149, no. 1, pp. 252–261, 2016.
Mediators of Inflammation

[31] S. M. Ryoo, J. Lee, Y. S. Lee et al., “Lactate level versus lactate clearance for predicting mortality in patients with septic shock defined by Sepsis-3,” *Critical Care Medicine*, vol. 46, no. 6, pp. e489–e495, 2018.

[32] B. Casserly, G. S. Phillips, C. Schorr et al., “Lactate measurements in sepsis-induced tissue hypoperfusion: results from the surviving sepsis campaign database,” *Critical Care Medicine*, vol. 43, no. 3, pp. 567–573, 2015.

[33] B. R. Don and G. Kaysen, “Poor nutritional status and inflammation: serum albumin: relationship to inflammation and nutrition,” *Seminars in Dialysis*, vol. 17, no. 6, pp. 432–437, 2004.

[34] A. R. Godinez-Vidal, A. Correa-Montoya, D. Enriquez-Santos, S. U. Perez-Escobedo, S. C. Lopez-Romero, and N. I. Gracida-Mancilla, ”Is albumin a predictor of severity and mortality in patients with abdominal sepsis?,” *Cirugia y Cirujanos*, vol. 87, no. 5, pp. 485–489, 2019.

[35] D. Davalos and K. Akassoglou, ”Fibrinogen as a key regulator of inflammation in disease,” *Seminars in Immunopathology*, vol. 34, no. 1, pp. 43–62, 2012.

[36] S. Q. Li, Y. H. Jiang, J. Lin et al., ”Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals,” *Cancer Medicine*, vol. 7, no. 4, pp. 1221–1231, 2018.

[37] W. M. Yang, W. H. Zhang, H. Q. Ying et al., ”Two new inflammatory markers associated with disease activity score-28 in patients with rheumatoid arthritis: albumin to fibrinogen ratio and C-reactive protein to albumin ratio,” *International Immunopharmacology*, vol. 62, pp. 293–298, 2018.

[38] S. Li, D. Zhang, S. Zeng et al., ”Prognostic value of preoperative albumin-to-fibrinogen ratio in patients with bladder cancer,” *Journal of Cancer*, vol. 12, no. 19, pp. 5864–5873, 2021.

[39] Y. He, J. Tang, B. Wu, B. Yang, Q. Ou, and J. Lin, ”Correlation between albumin to fibrinogen ratio, C-reactive protein to albumin ratio and Th17 cells in patients with rheumatoid arthritis,” *Clinica Chimica Acta*, vol. 500, pp. 149–154, 2020.